NCT06138353 (SXN-CVS) is a Phase 2, PHASE3 clinical trial of Shuxuening injection or placebo in Subarachnoid Hemorrhage, Aneurysmal, sponsored by Xiaolin Chen, MD.

Who is sponsoring NCT06138353?

NCT06138353 is sponsored by Xiaolin Chen, MD.

What drugs are being tested in NCT06138353?

Interventions in NCT06138353: Shuxuening injection or placebo.

What condition does NCT06138353 study?

NCT06138353 studies Subarachnoid Hemorrhage, Aneurysmal.

Is NCT06138353 still recruiting?

NCT06138353 is currently status unknown. Last updated 1 April 2024.

Last reviewed 2024-04-01 · How we verify

NCT06138353: SXN-CVS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shuxuening Injection for the Prevention of CVS in Patients With aSAH(SXN-CVS)

Status unknown Phase 2, PHASE3 Last updated 1 April 2024

What this trial tests

Phase 2, PHASE3 trial testing Shuxuening injection or placebo in Subarachnoid Hemorrhage, Aneurysmal in 50 participants. Status unknown.

Timeline

24 January 2024

Primary endpoint
30 November 2025

30 November 2025

Quick facts

Lead sponsor	Xiaolin Chen, MD
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	50
Start date	24 January 2024
Primary completion	30 November 2025
Estimated completion	30 November 2025
Sites	1 location across China

Drugs / interventions tested

Shuxuening injection or placebo — full drug profile →

Conditions studied

Subarachnoid Hemorrhage, Aneurysmal — all drugs for Subarachnoid Hemorrhage, Aneurysmal →

Sponsor

Xiaolin Chen, MD — full company profile →

Who can join

Adults 18 to 99, any sex, with Subarachnoid Hemorrhage, Aneurysmal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aneurysmal subarachnoid hemorrhage (SAH) is a frequent worldwide cause for stroke with a mortality of around 30%. Worldwide, almost 500 000 patients have aneurysmal SAH annually.An incidence of 2-16 cases of spontaneous SAH per 100 000 person-years was reported in a recent meta-analysis . Surgical treatment of aneurysms is essential in the acute phase of aSAH patients, either by surgical clipping or by endovascular embolization. Although there are many factors that influence the prognosis of patients with aSAH, cerebral vasospasm (CVS) and delayed cerebral ischemia (DCI) are the main factors contributing to the high mortality rate (30-40% within 30 days) and poor long-term functional prognosis of patients after aSAH. Cerebral vasospasm (CVS) is defined as focal or diffuse temporary narrowing of vessel diameter due to contraction of smooth muscle in the arterial wall, which can be detected by digital subtraction angiography (DSA), transcranial ultrasound Doppler (TCD), magnetic resonance (MR), and CT angiography (CTA) or visualised during intraoperative.The prevalence of CVS after aSAH is 67% , with symptomatic patients (symptomatic vasospasm) in 30-40% of them and leading to ischaemic events in 10-45% of patients. It usually begins 3-4 days after bleeding, peaks at 7-10 days and finally resolves at around 14-21 days. There is no effective treatment to prevent cerebral vasospasm events.Shuxuening Injection is a sterilized aqueous solution made by extraction of Ginkgo biloba. The study aims to clarify the clinical study of the efficacy and safety of Shuxuening Injection (10ml/branch) for the prophylactic of cerebral vasospasm (CVS) after aneurysmal subarachnoid hemorrhage.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Beyond the bleed: complications after aneurysmal subarachnoid hemorrhage. Pathophysiology, clinical implications, and management strategies: a review.
Busl KM, Bogossian EG, Claassen J, Helbok R, et al · · 2025 · cited 4× · PMID 41029753 · DOI 10.1186/s13054-025-05640-z

Verify or expand the search:

Other recruiting trials for Subarachnoid Hemorrhage, Aneurysmal

Currently open trials in the same condition.

NCT04696523 — Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage · Phase 2 · recruiting
NCT06819657 — Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid H · NA · recruiting
NCT06766422 — AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction · recruiting
NCT06906432 — Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage · recruiting
NCT06218654 — Hemodynamic Instability of Patient With Spontaneous Subarachnoid Hemorrhage · recruiting

Other Xiaolin Chen, MD trials

Trials by the same sponsor.

NCT07270419 — Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program · recruiting
NCT06061185 — Multimodal Computed Tomography in Patients With Acute Hemorrhagic Stroke · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06138353 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiaolin Chen, MD
Last refreshed: 1 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06138353.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing